FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers

AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Calquence (acalabrutinib) to treat adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity.

The FDA approval was based on data from the interim analyses of two phase III clinical trials, including Elevate-TN in patients with previously untreated CLL and Ascend in patients with relapsed or refractory CLL.

According to the company, both studies demonstrated that Calquence in combination with obinutuzumab or as monotherapy significantly minimised the relative risk of disease progression or death against the comparator arms in both first-line and relapsed or refractory CLL.

Elevate-TN is a randomised, multicentre and open-label Phase III study designed to assess the safety and efficacy of Calquence in combination with obinutuzumab or Calquence alone versus chlorambucil in combination with obinutuzumab in previously untreated patients with CLL.

Ascend is a global, randomised, multicentre and open-label phase III study designed to assess the efficacy of Calquence in previously treated patients with CLL.

Under the clinical development programme, AstraZeneca and Acerta Pharma are currently assessing Calquence in 23 company-sponsored clinical trials.

Calquence was already approved to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy in the US, Canada, Australia, Brazil, Qatar, UAE, Mexico, Argentina, Singapore, Chile and India.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types